Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Looking towards the future: what is in store for the treatment of bladder cancer?

Kirollos Hanna • 21 Mar 2018
HOPA 2018
Bladder Cancer Genitourinary Cancer Atezolizumab Cabozantinib Ramucirumab Tremelimumab
IMvigor130 RANGE

The future is looking bright for bladder cancer, with many clinical studies of new therapeutic options underway. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, provides an exciting overview of current clinical trials and discusses the challenges of treating second-line metastatic urothelial cancer. Just some of the exciting new drugs discussed include ramucirumab, cabozantinib and tremelimumab.

More from Kirollos Hanna

3:45
Updates on immunotherapy options for metastatic urothelial carcinoma
Kirollos Hanna • 21 Mar 2018
1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna • 21 Mar 2018
1:29
Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community
Kirollos Hanna • 21 Mar 2018
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna • 21 Mar 2018

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals